BRAF/MEK inhibitors have shown some promising activities across various malignancies with MAPK pathway alterations; however, further investigations are needed to find better treatments that have longer duration of responses and longer survival with more tolerable toxicities that would improve the quality of life of cancer patients. Here, MAP2K7 is linked to cancer.